In short
LRK-4189 is an investigational oral drug being studied in patients with solid tumors. It is currently in a Phase 1b-2 trial (NCT07498725) that plans to enroll 200 participants. The trial evaluates the safety, tolerability, and preliminary efficacy of LRK-4189 alone and in combination with chemotherapy in patients with metastatic colorectal cancer and other solid tumors.
Key points
- LRK-4189 is an investigational drug taken by mouth (orally).
- The current trial is Phase 1b-2 and plans to enroll 200 participants.
- The study includes patients with solid tumors, with a focus on metastatic colorectal cancer.
- The trial tests LRK-4189 alone and in combination with chemotherapy drugs such as fluorouracil and irinotecan.
- The study is currently authorised but not yet recruiting.
- Researchers are measuring safety, dose, and early signs of tumor response.
What is LRK-4189?
LRK-4189 is an investigational substance that has not yet received marketing authorisation. It is being developed as a potential treatment for solid tumors, a broad group of cancers that form solid masses in organs and tissues. The name LRK-4189 is a development code; no trade name has been assigned yet. The substance is given by mouth in the form of an oral preparation, according to the trial record.
How does LRK-4189 work?
The precise mechanism of action of LRK-4189 is not described in the available trial record. The trial is designed to evaluate its safety, tolerability, pharmacokinetics (how the body absorbs, distributes, and clears the drug), and pharmacodynamics (what the drug does to the body), which suggests that its mechanism is still being characterised. Because LRK-4189 is being tested in colorectal cancer, and the supplementary sources discuss protein kinase pathways in colorectal cancer cells, it may be relevant to note that some investigational compounds in this field aim to modulate protein kinase signalling. However, no source provided here states that LRK-4189 itself acts on protein kinases.
Which conditions is it studied for?
The clinical trial of LRK-4189 includes patients with the following conditions:
- Solid tumors — a general category of cancers that form solid masses, including cancers of the colon, rectum, lung, breast, and other organs.
- Metastatic colorectal cancer (mCRC) — colorectal cancer that has spread to other parts of the body. The trial summary specifically mentions evaluating preliminary efficacy in patients with metastatic colorectal cancer.
How is LRK-4189 given?
LRK-4189 is given by mouth (orally). The trial record lists LRK-4189 as an oral drug, and it is being tested both alone and in combination with other cancer medicines that are given by intravenous infusion or injection, including fluorouracil, folinic acid, irinotecan, and oxaliplatin. The combination partners are standard chemotherapy drugs used in colorectal cancer treatment.
What do the clinical trials show?
There is currently one clinical trial of LRK-4189 registered in the public records provided. It is a Phase 1b-2 study with a planned enrollment of 200 participants. The trial is authorised, meaning it has received regulatory approval to proceed but is not yet recruiting or ongoing according to the available status. The study is divided into three parts. Part 1 aims to identify an appropriate dose of LRK-4189 for initial expansion, either the active dose or the maximum tolerated dose. Part 2 evaluates preliminary efficacy in patients with metastatic colorectal cancer. Part 3 determines the optimal dose of LRK-4189 in specific indications.
The trial measures several outcomes. In Part 1, researchers look at the incidence, type, and severity of adverse events and serious adverse events, dose-limiting toxicity, treatment interruptions and discontinuations, safety laboratory results, and pharmacokinetic parameters. If feasible, they also measure pharmacodynamic parameters and shrinkage of target lesions. In Part 2, the main efficacy measures are objective response rate (the proportion of patients whose tumors shrink or disappear), disease control rate, duration of response, progression-free survival (how long patients live without their cancer worsening), and overall survival. Part 3 combines safety and efficacy measures.
Because this is a Phase 1b-2 study, the primary goal is to establish safety and dosing rather than to prove effectiveness. No results are yet available from this trial.
What side effects are known?
The side effects of LRK-4189 are not yet known from clinical experience. The trial is designed to collect information on adverse events and serious adverse events, including their severity and whether they are related to treatment. The supplementary sources provided do not describe side effects specific to LRK-4189.